Latest Industry News & Trends

Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with companies executive. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.

Recently Added News

9/24/2021
BreakingPharmaRegulationRetina
US, UK Join EU in Approving First Ranibizumab Biosimilar Byooviz
US, UK Join EU in Approving First Ranibizumab Biosimilar Byooviz

The UK and US have joined the European Union in approving their first ranibizumab biosimilar, Byooviz, a Samsung Bioepis product that references Lucentis. EU approval was handed down Aug. 18. UK ap...

9/24/2021
BreakingDealsDiagnostic
Diagnostic Device Makers Luneau, Optovue Announce Merger
Diagnostic Device Makers Luneau, Optovue Announce Merger

Ophthalmic diagnostic device manufacturers Luneau Technology, of France, and Optovue, of Fremont, California, have announced an agreement to merge. Terms of the deal were not disclosed. The compani...

9/24/2021
BreakingClinical TrialDry EyePharma
Aerie Removes CEO After Dry Eye Candidate Misses Phase IIb Targets
Aerie Removes CEO After Dry Eye Candidate Misses Phase IIb Targets

Aerie Pharmaceuticals announced Sept. 21 that it had terminated longtime chairman and chief executive officer Vicente Anido, PhD, just days after the company reported that its dry eye candidate AR-...

9/24/2021
BreakingClinical TrialDry EyePharma
Nicox Blepharitis Candidate NCX 4251 Misses Endpoints in Phase IIb Trial  
Nicox Blepharitis Candidate NCX 4251 Misses Endpoints in Phase IIb Trial

French company Nicox announced Sept. 23 that NCX 4251, its candidate for blepharitis, failed to meet its primary or secondary endpoints in the MISSISSIPPI Phase IIb trial. NCX 4251 is a novel paten...

9/24/2021
BreakingCataractDealsPharma
Arctic Vision Adds Mydriatic Candidate MydCombi to Eyenovia License Deal

China’s Arctic Vision announced Sept. 16 that it would expand its exclusive license agreement with Eyenovia to include a third asset, mydriatic candidate MydCombi, for development and commercializa...

9/24/2021
AcquisitionsBreakingDealsGene TherapyRetina
Novartis Acquires Arctos Medical, Expanding Optogenetic Gene Therapy Pipeline
Novartis Acquires Arctos Medical, Expanding Optogenetic Gene Therapy Pipeline

Swiss company Novartis announced Sept. 21 that it had acquired Arctos Medical, developer of a potential optogenetic AAV gene therapy for inherited retinal disease. Financial details were not disclo...

9/24/2021
BreakingDealsGene TherapyRetina
Coave, Théa to Co-develop Gene Therapy Candidate for PDE6b-Associated RP
Coave, Théa to Co-develop Gene Therapy Candidate for PDE6b-Associated RP

French companies Coave Therapeutics and Théa have agreed to co-develop Coave’s gene therapy candidate CTx-PDE6b for patients with PDE6b-associated retinitis pigmentosa. Théa will make an upfront pa...

9/24/2021
BreakingDealsDry EyePharma
Glaukos Licenses Attillaps’ Compounds to Eradicate Demodex Mites
Glaukos Licenses Attillaps’ Compounds to Eradicate Demodex Mites

Glaukos announced Sept. 20 that it had entered into a licensing agreement with Attillaps Holdings granting Glaukos global rights to develop and commercialize Attillaps’ library of compounds that ta...

9/24/2021
BreakingFundingGene TherapyRetina
Retinal Degeneration Fund Launches Opus Genetics with $19 Million in Seed Funding
Retinal Degeneration Fund Launches Opus Genetics with $19 Million in Seed Funding

The Retinal Degeneration Fund (RD Fund), the venture arm of the Foundation Fighting Blindness, announced Sept. 22 that it had launched Opus Genetics to develop gene therapies for orphan inherited r...

9/22/2021
MeetingNewsletterRetina
2021 Euretina Congress Draws Record Turnout, Lauds Controversy as Educational
2021 Euretina Congress Draws Record Turnout, Lauds Controversy as Educational

Thomas Wolfensberger, MD, captured the spirit of the 2021 Euretina congress when he praised the meeting’s debates by paraphrasing a quote that he never learned anything from anyone who agreed with ...

9/22/2021
NewsletterRevenue
Ophthalmic Company Revenue Increases 44.2 Percent in Second Quarter of 2021
Ophthalmic Company Revenue Increases 44.2 Percent in Second Quarter of 2021

Overall ophthalmic revenue in Q2-2021 totaled $11.1 billion, indicating a strong recovery from a pandemic-impacted Q2-2020. Eight public companies reported record-high earnings in Q2-2020 compared ...

9/22/2021
NewsletterSurgical
Surgeons Report 65.6 Percent Increase in Q2-2021 Ophthalmic Procedure Volume
Surgeons Report 65.6 Percent Increase in Q2-2021 Ophthalmic Procedure Volume

US ophthalmologists reported that ophthalmic procedures increased 65.6 percent in Q2-2021 compared with COVID-19-impacted Q2-2020, according to Market Scope’s latest surveys. Year-over-year perform...

Past News Stories

9/22/2021
ChinaMeetingNewsletter
APAO Virtual Meeting Focuses on Changes in Delivery of Eye Care
APAO Virtual Meeting Focuses on Changes in Delivery of Eye Care

The 36th Asia-Pacific Academy of Ophthalmology (APAO) Congress convened on a virtual platform on Sept. 5 after the COVID-19 pandemic forced the cancellation of the 2020 meeting. During the course o...

9/22/2021
NewsletterPharmaRegulationRetina
Byooviz Becomes First Ranibizumab Biosimilar Approved in the EU, UK, US
Byooviz Becomes First Ranibizumab  Biosimilar Approved in the EU, UK, US

The European Union, UK, and US all have approved their first ranibizumab biosimilar, Byooviz, a Samsung Bioepis product that references Lucentis. EU approval was handed down Aug. 18. UK approval fo...

9/22/2021
ChinaNewsletterPresbyopia
Arctic Vision Gets Green Light for China’s First Phase III Study of Presbyopia Treatment
Arctic Vision Gets Green Light for China’s First Phase III Study of Presbyopia Treatment

Arctic Vision announced Sept. 2 that Chinese regulators had given it the go-ahead to begin a Phase III study of ARVN003 (pilocarpine microdose ophthalmic solution) for the treatment of presbyopia. ...

9/22/2021
CataractNewsletterPharma
Melt Secures Financing for Trial of Candidate for Pain and Sedation
Melt Secures Financing for Trial of Candidate for Pain and Sedation

Melt Pharmaceuticals announced Sept. 2 that it plans to begin a Phase II study of its pain and sedation drug candidate, MELT-300, after receiving a $13.5 million senior secured loan from parent Har...

9/22/2021
NewsletterRegulationTelehealth
Solving Ophthalmic Telehealth Issues Requires New Tech and Regulatory Clarity, Surgeon Says
Solving Ophthalmic Telehealth Issues Requires New Tech and Regulatory Clarity, Surgeon Says

Telehealth’s future in ophthalmology is teetering between potential and uncertainty, according to Grayson W. Armstrong, MD, MPH, an ophthalmologist at Massachusetts Eye and Ear in Boston and instru...

9/22/2021
DiagnosticIOLNewsletterRegulationSingle-Use
Select US FDA Approvals and Clearances in August 2021
Select US FDA Approvals and Clearances in August 2021

The US FDA granted two clearances through the ophthalmic device division using the 510(k) pathway in August 2021, according to the agency’s database. CenterVue gained clearance for additional featu...

9/22/2021
FundingGlaucomaNewsletter
Two Research Grants Are Among Latest Ophthalmic Fundraising
Two Research Grants Are Among Latest Ophthalmic Fundraising

The Gilbert Family Foundation, based in Detroit, is funding a study to investigate optic pathway tumors in patients with neurofibromatosis type 1. Entrepreneur Steve Kirsch is supporting a collabor...

9/22/2021
DealsGene TherapyNewsletterRetina
AbbVie, Regenxbio to Partner on Wet AMD Gene Therapy Candidate
AbbVie, Regenxbio to Partner on Wet AMD Gene Therapy Candidate

AbbVie and Regenxbio announced Sept. 13 that they would partner to develop and commercialize RGX-314, a potential one-time gene therapy for the treatment of wet age-related macular degeneration (we...

9/22/2021
DiagnosticNewsletterRetina
New Diagnostic Testing of Astronauts’ Vision Uses Mobile Technology, Machine-Learning
New Diagnostic Testing of Astronauts’ Vision Uses Mobile Technology, Machine-Learning

European researchers are testing a new way to monitor astronaut eye health with diagnostic equipment that launched to the International Space Station on Aug. 29 from NASA’s Kennedy Space Center in ...

9/22/2021
DeviceGlaucomaNewsletterSurgical
Ivantis Settles Glaukos’ Patent Suit, Faces Another from Sight Sciences
Ivantis Settles Glaukos’ Patent Suit, Faces Another from Sight Sciences

Just as Glaukos and Ivantis were reporting a settlement in the patent infringement lawsuit filed by Glaukos against Ivantis’ Hydrus Microstent glaucoma device, Sight Sciences issued its own legal c...

9/22/2021
DeviceGlaucomaNewsletterRegulationSurgical
Glaukos Files for Supplemental Approval in US of iStent Infinite
Glaukos Files for Supplemental Approval in US of iStent Infinite

Glaukos announced Sept. 3 that it had submitted a supplemental premarket approval (PMA) application to the US FDA for the iStent Infinite trabecular micro-bypass system for glaucoma. The Infinite w...

9/22/2021
COVID-19NewsletterSingle-UseSurgical
COVID-19 Backlog to Boost Single-Use Device Market 6 Percent
COVID-19 Backlog to Boost Single-Use Device Market 6 Percent

Global increases in ophthalmic surgery—driven by a pandemic-created surgery backlog and the world’s aging population—will lead to nearly 6 percent per year revenue growth in single-use surgical dev...

Want to Read the Full Article?

Register A Corporate Account

A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.

Select one or more
Select one or more